CL2016003092A1 - “compuestos derivados de pirazol sustituido, bloqueadores de canales de calcio tipo t; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, enfermedades del snc, cardiovasculares, neuropatía diabética, infertilidad y disfunción sexual”. pct - Google Patents

“compuestos derivados de pirazol sustituido, bloqueadores de canales de calcio tipo t; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, enfermedades del snc, cardiovasculares, neuropatía diabética, infertilidad y disfunción sexual”. pct

Info

Publication number
CL2016003092A1
CL2016003092A1 CL2016003092A CL2016003092A CL2016003092A1 CL 2016003092 A1 CL2016003092 A1 CL 2016003092A1 CL 2016003092 A CL2016003092 A CL 2016003092A CL 2016003092 A CL2016003092 A CL 2016003092A CL 2016003092 A1 CL2016003092 A1 CL 2016003092A1
Authority
CL
Chile
Prior art keywords
cancer
treatment
pharmaceutical composition
cns
type
Prior art date
Application number
CL2016003092A
Other languages
English (en)
Inventor
Romain Siegrist
Bibia Heidmann
Simon Stamn
John Gatfield
Olivier Bezencon
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2016003092A1 publication Critical patent/CL2016003092A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA SOLICITUD SE REFIERE A COMPUESTOS DERIVADOS DE PIRAZOL SUSTITUIDO, BLOQUEADORES DE CANALES DE CALCIO TIPO T, A UNA COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y A SU USO EN EL TRATAMIENTO DEL CÁNCER, ENFERMEDADES DEL SNC, CARDIOVASCULARES, NEUROPATÍA DIABÉTICA, INFERTILIDAD Y DISFUNCIÓN SEXUAL.
CL2016003092A 2014-06-03 2016-12-01 “compuestos derivados de pirazol sustituido, bloqueadores de canales de calcio tipo t; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, enfermedades del snc, cardiovasculares, neuropatía diabética, infertilidad y disfunción sexual”. pct CL2016003092A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2014061901 2014-06-03

Publications (1)

Publication Number Publication Date
CL2016003092A1 true CL2016003092A1 (es) 2017-05-12

Family

ID=53385705

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003092A CL2016003092A1 (es) 2014-06-03 2016-12-01 “compuestos derivados de pirazol sustituido, bloqueadores de canales de calcio tipo t; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, enfermedades del snc, cardiovasculares, neuropatía diabética, infertilidad y disfunción sexual”. pct

Country Status (32)

Country Link
US (2) US9932314B2 (es)
EP (1) EP3152199B1 (es)
JP (1) JP6195684B2 (es)
KR (1) KR101906031B1 (es)
CN (1) CN106414429B (es)
AR (1) AR100712A1 (es)
AU (1) AU2015270118C1 (es)
CA (1) CA2947002C (es)
CL (1) CL2016003092A1 (es)
CY (1) CY1120864T1 (es)
DK (1) DK3152199T3 (es)
EA (1) EA031104B1 (es)
ES (1) ES2696351T3 (es)
HR (1) HRP20181670T1 (es)
HU (1) HUE040489T2 (es)
IL (1) IL249275B (es)
LT (1) LT3152199T (es)
MA (1) MA40281B1 (es)
MX (1) MX2016015923A (es)
NZ (1) NZ727818A (es)
PE (1) PE20170129A1 (es)
PH (1) PH12016502230B1 (es)
PL (1) PL3152199T3 (es)
PT (1) PT3152199T (es)
RS (1) RS57943B1 (es)
SG (1) SG11201609974PA (es)
SI (1) SI3152199T1 (es)
TN (1) TN2016000542A1 (es)
TR (1) TR201816624T4 (es)
TW (2) TWI675827B (es)
WO (1) WO2015186056A1 (es)
ZA (1) ZA201608821B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3152199T3 (en) 2014-06-03 2018-11-26 Idorsia Pharmaceuticals Ltd PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
AU2015317022B2 (en) 2014-09-15 2020-01-16 Idorsia Pharmaceuticals Ltd Triazole compounds as T-type calcium channel blockers
KR102486298B1 (ko) * 2016-02-09 2023-01-06 인벤티스바이오 엘엘씨 인돌아민-2,3-디옥시게나아제(ido)의 억제제
JP7120549B2 (ja) * 2016-12-15 2022-08-17 小野薬品工業株式会社 Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
CA3046846A1 (en) * 2016-12-16 2018-06-21 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
US20210128537A1 (en) * 2016-12-21 2021-05-06 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
TWI808960B (zh) * 2017-02-06 2023-07-21 瑞士商愛杜西亞製藥有限公司 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法
CN110831932A (zh) * 2017-07-05 2020-02-21 爱杜西亚药品有限公司 晶体形式的n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-环丙基)-苯基]-乙酰胺
CA3085388A1 (en) 2017-12-12 2019-06-20 Queen's University At Kingston Compounds and methods for inhibiting cyp26 enzymes
CN114340670A (zh) 2019-07-11 2022-04-12 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
EP3997068A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
WO2021123949A1 (en) 2019-12-20 2021-06-24 Idorsia Pharmaceuticals Ltd Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
CA3221122A1 (en) * 2021-07-02 2023-01-05 Seok Ju Lee Method for preparing intermediate for synthesis of xanthine oxidase inhibitor
WO2023240205A1 (en) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Deuterated compounds

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526790T2 (de) 1994-06-24 2003-03-06 Euro Celtique Sa Verbindungen zur hemmung von phosphodiesrerase iv
WO1998028269A1 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
WO2002053160A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ivb
WO2002053101A2 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
CA2465207C (en) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
ES2295441T3 (es) 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
CA2469821C (en) 2001-12-18 2009-10-20 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
EP1613614A2 (en) 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US7268151B2 (en) 2003-04-04 2007-09-11 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
CA2525325A1 (en) * 2003-05-01 2004-11-18 Abbott Laboratories Pyrazole-amides and sulfonamides as sodium channel modulators
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
ES2361845T3 (es) 2004-08-18 2011-06-22 Pfizer, Inc. Inhibidores de arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones y tratamientos que utilizan los mismos.
AR052429A1 (es) 2004-12-23 2007-03-21 Glaxo Group Ltd Compuesto de arilpiridina, composicion farmaceutica que lo comprende, su uso para l a eleboracion de un medicamento y procedimiento para prepararlo
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
FR2889234B1 (fr) * 2005-07-27 2007-11-23 Andre Prieur Arret de porte a positions de maintien indeterminees
KR100654328B1 (ko) * 2005-08-26 2006-12-08 한국과학기술연구원 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법
CA2634147A1 (en) 2005-12-22 2007-06-28 Icagen, Inc. Calcium channel antagonists
MX2008013238A (es) * 2006-04-12 2008-10-21 Merck & Co Inc Antagonistas de los canales de calcio de tipo t de piridil amida.
EP2046755A2 (en) * 2006-07-24 2009-04-15 F. Hoffmann-Roche AG Pyrazoles as glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008085888A1 (en) 2007-01-05 2008-07-17 Arena Pharmaceuticals, Inc. G protein-coupled receptor and modulators thereof for the treatment of gaba-related neurological disorders including sleep-related disorders
AU2008266883B2 (en) 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CN101827832B (zh) * 2007-10-08 2014-05-07 阿德维纳斯治疗私人有限公司 作为葡糖激酶活化剂的乙酰胺衍生物、其制备方法及医药应用
US8637513B2 (en) 2007-10-24 2014-01-28 Merck Sharp & Dohme Corp. Heterocycle phenyl amide T-type calcium channel antagonists
CA2702126A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
CA2703471A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Pyrazinyl amide t-type calcium channel antagonists
WO2009118596A2 (en) * 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Phthalimide derivatives as trpa1 modulators
AU2009231258A1 (en) 2008-04-04 2009-10-08 Biomarin Iga Limited Compounds for treating muscular dystrophy
WO2010004390A1 (en) 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
KR101052065B1 (ko) * 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
CA2749893A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
WO2010122089A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited N-pyrazolyl carboxamides as crac channel inhibitors
JP5596137B2 (ja) 2009-06-04 2014-09-24 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン誘導体
WO2011022315A1 (en) 2009-08-19 2011-02-24 Merck Sharp & Dohme Corp. Pyrazinyl phenyl amide t-type calcium channel antagonists
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
WO2011053542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
CA2782885A1 (en) 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
WO2012027322A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
MX341977B (es) 2011-03-07 2016-09-07 Pfizer Derivados de fluoro-piridinona utiles como agentes antibacterianos.
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9868748B2 (en) * 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
AR096393A1 (es) 2013-05-23 2015-12-30 Bayer Cropscience Ag Compuestos heterocíclicos pesticidas
EP2848615A1 (en) * 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
KR101685993B1 (ko) 2014-05-15 2016-12-13 한국과학기술연구원 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
DK3152199T3 (en) 2014-06-03 2018-11-26 Idorsia Pharmaceuticals Ltd PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
AU2015317022B2 (en) 2014-09-15 2020-01-16 Idorsia Pharmaceuticals Ltd Triazole compounds as T-type calcium channel blockers
PT3250563T (pt) 2015-01-30 2022-02-09 Neurocrine Biosciences Inc Triazois substituídos e métodos relacionados aos mesmos
WO2016138472A1 (en) * 2015-02-27 2016-09-01 Calcimedica, Inc. Pancreatitis treatment

Also Published As

Publication number Publication date
EP3152199A1 (en) 2017-04-12
RS57943B1 (sr) 2019-01-31
AU2015270118A1 (en) 2017-01-12
NZ727818A (en) 2020-06-26
MA40281B1 (fr) 2018-11-30
US9932314B2 (en) 2018-04-03
IL249275B (en) 2020-01-30
IL249275A0 (en) 2017-02-28
JP2017516830A (ja) 2017-06-22
AU2015270118C1 (en) 2019-11-28
BR112016028315A8 (pt) 2017-12-26
ES2696351T3 (es) 2019-01-15
US20180105496A1 (en) 2018-04-19
KR101906031B1 (ko) 2018-10-08
TR201816624T4 (tr) 2018-11-21
AU2015270118B2 (en) 2019-09-12
ZA201608821B (en) 2019-05-29
EA031104B1 (ru) 2018-11-30
EA201692521A1 (ru) 2017-05-31
HUE040489T2 (hu) 2019-03-28
PH12016502230A1 (en) 2017-01-09
DK3152199T3 (en) 2018-11-26
JP6195684B2 (ja) 2017-09-13
TWI675827B (zh) 2019-11-01
PE20170129A1 (es) 2017-03-30
TWI690513B (zh) 2020-04-11
AR100712A1 (es) 2016-10-26
CA2947002A1 (en) 2015-12-10
SI3152199T1 (sl) 2018-12-31
MA40281A (fr) 2015-12-10
CN106414429A (zh) 2017-02-15
WO2015186056A1 (en) 2015-12-10
CY1120864T1 (el) 2019-12-11
PL3152199T3 (pl) 2019-01-31
TN2016000542A1 (en) 2018-04-04
EP3152199B1 (en) 2018-08-15
CN106414429B (zh) 2020-01-03
SG11201609974PA (en) 2016-12-29
PH12016502230B1 (en) 2017-01-09
BR112016028315A2 (pt) 2017-08-22
PT3152199T (pt) 2018-11-26
US20170096399A1 (en) 2017-04-06
TW201625551A (zh) 2016-07-16
LT3152199T (lt) 2018-11-12
US10065929B2 (en) 2018-09-04
CA2947002C (en) 2023-01-03
HRP20181670T1 (hr) 2018-12-14
TW201930270A (zh) 2019-08-01
KR20170012432A (ko) 2017-02-02
MX2016015923A (es) 2017-02-27

Similar Documents

Publication Publication Date Title
CL2016003092A1 (es) “compuestos derivados de pirazol sustituido, bloqueadores de canales de calcio tipo t; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, enfermedades del snc, cardiovasculares, neuropatía diabética, infertilidad y disfunción sexual”. pct
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2018001230A1 (es) Tratamiento de osteoartritis
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2016002751A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
EA202092435A2 (ru) Моноклональные антитела против bcma
CL2016000783A1 (es) “compuestos derivados de isoquinolinona y quinazolinona, inhibidores pi3k; composición farmacéutica que los comprende; útiles en el tratamiento del cáncer, enfermedades inflamatorias y autoinmune”. pct
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
AR102712A1 (es) Agonistas parciales del receptor de insulina
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CL2016002615A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
CL2016002678A1 (es) “compuestos derivados de heteroarilo, ligantes d1; composición farmacéutica que los comprende; útiles en el tratamiento de enfermedades del snc, autoinmune, metabólicas, entre otras”. pct
EA201890572A1 (ru) Биофармацевтические композиции
CL2016002497A1 (es) “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct